ELI LILLY AND CO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has seven approved drugs.
There are seventeen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and forty-eight patent family members on ELI LILLY AND CO drugs in fifty-five countries and forty-four supplementary protection certificates in eighteen countries.
Summary for ELI LILLY AND CO
| International Patents: | 348 |
| US Patents: | 17 |
| Tradenames: | 9 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for ELI LILLY AND CO: | See patent lawsuits for ELI LILLY AND CO |
| PTAB Cases with ELI LILLY AND CO as petitioner: | See PTAB cases with ELI LILLY AND CO as petitioner |
| PTAB Cases with ELI LILLY AND CO as patent owner: | See PTAB cases with ELI LILLY AND CO as patent owner |
Drugs and US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-005 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-010 | Jul 28, 2023 | RX | Yes | Yes | 9,474,780 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-008 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 5,114,976*PED | ⤷ Try a Trial |
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 4,971,998*PED | ⤷ Try a Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,194,009 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for ELI LILLY AND CO Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6219534 | ⤷ Try a Trial |
| Japan | 5114496 | ⤷ Try a Trial |
| South Korea | 20110091551 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ELI LILLY AND CO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | C20190008 00271 | Estonia | ⤷ Try a Trial | PRODUCT NAME: ABEMATSIKLIIB;REG NO/DATE: EU/1/18/1307 01.10.2018 |
| 2379528 | 2019C/507 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| 2288610 | 2017033 | Norway | ⤷ Try a Trial | PRODUCT NAME: BARICITINIB OG FARMASOEYTISK; REG. NO/DATE: EU/1/16/1170 20170222 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
